Next-gen NK Cell therapy; entering Ph 2 trials in 1H19 (AML HSCT transplant) with RMAT potential in 2H20. Ph 1/2 demonstrated signif reduction in relapse rates (MD Anderson). Positive pre-IND feedback. Patented nanoparticle processing tech enables high-dose, high-potency NK cells from commercial CDMO. Addl programs in PC: relapsed/refractory AML, MM (partnered), ovarian cancer. Medical co-founders: Dr. Dean Lee (Nationwide Children’s) & Stefan Ciurea (MDACC). Executive Chairman: Phil McKee, Cancer Survivor and Founder of TurboChef. Self-funded through enrollment of initial Ph 1/2 dosing cohorts.
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.